clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
De Wit S et al. Acquired resistance to clarithromycin as combined therapy in Mycobacterium avium intracellulare infection. 1993 Lancet pmid:8093299
Maurin M and Raoult D In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin. 1993 Antimicrob. Agents Chemother. pmid:8109928
Parish LC Clarithromycin in the treatment of skin and skin structure infections: two multicenter clinical studies. Clarithromycin Study Group. 1993 Int. J. Dermatol. pmid:8340194
Lazard T et al. Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with Mycobacterium avium. 1993 Antimicrob. Agents Chemother. pmid:8215285
Pialoux G et al. Combination antibiotic treatment with clarithromycin for human immunodeficiency virus-associated Rhodococcus equi infection. 1993 Clin. Infect. Dis. pmid:8218702
Clinical Perspectives on Clarithromycin in Pediatric Infections. Symposium proceedings. February 19-20, 1993. 1993 Pediatr. Infect. Dis. J. pmid:7905199
Fraschini F et al. Clarithromycin clinical pharmacokinetics. 1993 Clin Pharmacokinet pmid:8222460
Neu HC and Chick TW Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. 1993 Chest pmid:8222794
Kodama R et al. [Eradication therapy of Helicobacter pylori in gastroduodenal ulcer and its long-term course]. 1993 Nippon Rinsho pmid:8283646
Roig J et al. Treatment of Legionnaires' disease. Current recommendations. 1993 Drugs pmid:7691508
Ragnaud JM et al. [Cerebral toxoplasmosis in AIDS. 73 cases. Clinical Epidemiology Group on AIDS in Aquitania]. 1993 Presse Med pmid:8378280
Hoffner SE et al. Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations. 1993 Antimicrob. Agents Chemother. pmid:8392308
Gevaudan MJ et al. In-vitro evaluation of clarithromycin, temafloxacin, and ethambutol in combination against Mycobacterium avium complex. 1993 J. Antimicrob. Chemother. pmid:8392998
Wallace RJ et al. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. 1993 Ann. Intern. Med. pmid:8357113
Wettengel R et al. Clarithromycin versus cefaclor for the treatment of mild-to-moderate acute bacterial bronchitis. 1993 J. Antimicrob. Chemother. pmid:8360133
Nakashio S et al. [Antimicrobial activity of clarithromycin and its effect on bacterial adherence to medical material]. 1993 Jpn J Antibiot pmid:8360978
Lonks JR and Medeiros AA High rate of erythromycin and clarithromycin resistance among Streptococcus pneumoniae isolates from blood cultures from Providence, R.I. 1993 Antimicrob. Agents Chemother. pmid:8239578
Guay DR et al. Overview of the tolerability profile of clarithromycin in preclinical and clinical trials. 1993 Drug Saf pmid:8504017
Dever LL et al. Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi. 1993 Antimicrob. Agents Chemother. pmid:8215288
Fass RJ Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. 1993 Antimicrob. Agents Chemother. pmid:8257127
Watanabe Y et al. Chemical modification of erythromycins. XII. A facile synthesis of clarithromycin (6-O-methylerythromycin A) via 2'-silylethers of erythromycin A derivatives. 1993 J. Antibiot. pmid:8360112
Ruf B et al. Effectiveness of the macrolide clarithromycin in the treatment of Mycobacterium avium complex infection in HIV-infected patients. 1992 Sep-Oct Infection pmid:1428183
Friend DR Polyacrylate resin microcapsules for taste masking of antibiotics. 1992 Oct-Dec J Microencapsul pmid:1403495
de Campora E et al. Comparative efficacy and safety of roxithromycin and clarithromycin in upper respiratory tract infections. 1992 May-Jun Diagn. Microbiol. Infect. Dis. pmid:1535578
Nilsen OG et al. Macrolide pharmacokinetics and dose scheduling of roxithromycin. 1992 May-Jun Diagn. Microbiol. Infect. Dis. pmid:1535579
Hoover WW et al. Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycin. 1992 Mar-Apr Diagn. Microbiol. Infect. Dis. pmid:1533827
Chapelsky MC et al. Renal tubular enzyme effects of clarithromycin in comparison with gentamicin and placebo in volunteers. 1992 Jul-Aug Drug Saf pmid:1355971
Logan RP et al. Clarithromycin and omeprazole for Helicobacter pylori. 1992 Lancet pmid:1353155
Hammerschlag MR et al. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. 1992 Antimicrob. Agents Chemother. pmid:1324650
Paulsen P et al. Influence of azithromycin and other macrolides on the intracellular killing of Staphylococcus aureus by human polymorphonuclear leucocytes of healthy donors and a patient with Chédiak-Higashi syndrome. 1992 Chemotherapy pmid:1324831
Ruf B et al. Acquired resistance of MAI to clarithromycin. 1992 Am. Rev. Respir. Dis. pmid:1533999
Chonmaitree T et al. Effect of viral respiratory tract infection on outcome of acute otitis media. 1992 J. Pediatr. pmid:1534364
Knothe H [Short-term therapy of acute respiratory and ORL infections with Clarithromycin]. 1992 Z Gesamte Inn Med pmid:9022402
Berk SL New macrolide antibiotics. 1992 Ann. Intern. Med. pmid:1386966
Yajko DM et al. Comparison of the intracellular activities of clarithromycin and erythromycin against Mycobacterium avium complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals. 1992 Antimicrob. Agents Chemother. pmid:1387302
de Lalla F et al. Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. 1992 Antimicrob. Agents Chemother. pmid:1387303
Ji B et al. Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice. 1992 Int. J. Lepr. Other Mycobact. Dis. pmid:1338596
Yajko DM In vitro activity of antimicrobial agents against the Mycobacterium avium complex inside macrophages from HIV1-infected individuals: the link to clinical response to treatment? 1992 Res. Microbiol. pmid:1455069
Omura S et al. [Research and development of clarithromycin]. 1992 Yakugaku Zasshi pmid:1469609
Chu SY et al. Clarithromycin pharmacokinetics in healthy young and elderly volunteers. 1992 J Clin Pharmacol pmid:1474166
Gelber RH et al. Clarithromycin at very low levels and on intermittent administration inhibits the growth of M. leprae in mice. 1992 Int. J. Lepr. Other Mycobact. Dis. pmid:1474290
Heifets LB et al. Bacteriostatic and bactericidal activities of gentamicin alone and in combination with clarithromycin against Mycobacterium avium. 1992 Antimicrob. Agents Chemother. pmid:1416852
Brown BA et al. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. 1992 Antimicrob. Agents Chemother. pmid:1416891
Biehle J and Cavalieri SJ In vitro susceptibility of Mycobacterium kansasii to clarithromycin. 1992 Antimicrob. Agents Chemother. pmid:1416897
Chu SY et al. Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. 1992 Antimicrob. Agents Chemother. pmid:1489187
Araujo FG et al. Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis. 1992 Antimicrob. Agents Chemother. pmid:1489188
Gan VN et al. Pharmacokinetics of a clarithromycin suspension in infants and children. 1992 Antimicrob. Agents Chemother. pmid:1489191
Sturgill MG and Rapp RP Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles. 1992 Ann Pharmacother pmid:1421677
Denny FW Current management of streptococcal pharyngitis. 1992 J Fam Pract pmid:1453145
Schrock CG Clarithromycin vs penicillin in the treatment of streptococcal pharyngitis. 1992 J Fam Pract pmid:1453146